Journals / SSK Tepecik Eğitim Hastanesi Dergisi / 2003 / Cilt: 13 - Sayı: 2

Plasma homocystein levels in acute coronary syndrome patients

Akut koroner sendrom'lu hastalarda plazma homosistein düzeyleri

Pages
91–96
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This conflict may be solved when the ongoing trials will give us new data on the subject.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Traditional risk factors for atherosclerotic cardiovascular diseases (family history, gender, hypertension, dyslipidemia, diabetes, smoking, central obesity) which are well defined in the past three decades are not satisfactory to define the high incidence of coronary arterial disease.
📊
Key Findings & Data:Elevated plasma levels of this ammo acid can increase the risk of cardiovascular disease.
💡
Conclusion & Impact:This conflict may be solved when the ongoing trials will give us new data on the subject.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Koroner hastalık · Sendrom · Akut hastalık

Abstract

Aim: Traditional risk factors for atherosclerotic cardiovascular diseases (family history, gender, hypertension, dyslipidemia, diabetes, smoking, central obesity) which are well defined in the past three decades are not satisfactory to define the high incidence of coronary arterial disease. New evidences emphasize that homocystein may play an important role in the cardiovascular risk puzzle. Elevated plasma levels of this ammo acid can increase the risk of cardiovascular disease. The mechanisms of this risk elevation have not been clearly identified yet. Methods: In this study, 20 patients with Acute Coronary Syndrome (ACS) and 20 healthy controls were investigated. Mean plasma homocystein values of the groups were compared. Both of the groups were subgrouped and analyzed by smoking habitus and gender.Results: In our study, patient group had higher plasma homocystein levels than the control group but no statistically significant difference was obtained (p>0.05). In the patient group, smokers had significantly higher levels (p$\leq$0.05). Conclusion: Many clinicians believe that hyperhomocyteinemia is a risk factor for atherosclerosis. Case -control studies and some meta analysis trials showed that, high plasma homocystein levels is a good predictor of coronary heart disease. However, there is no clear evidence that decreasing of hyperhomosyteinemia is beneficial in primary and secondary prevention. This conflict may be solved when the ongoing trials will give us new data on the subject.

Özet

Amaç: Aterosklerotik kardiyovasküler hastalık geleneksel risk faktörleri (ailevi yatkınlık, cinsiyet, hipertansiyon, dislipidemi, diyabet, obesite, sigara kullanımı) /coroner arter hastalığının yüksek sıklığını tamamen açıklayamamaktadır. Yeni kanıtlar kardiyouasküler risk bulmacasında plazma homosistein düzeyinin yüksek olmasının önemli bir role sahip olabileceğini göstermektedir. Çalışmamızda Akut Koroner Sendrom (AKS) tanısı almış hastalarda plazma homosistein düzeylerinin yüksek olup olmadığı araştırılmıştır. Yöntem: Çalışmamıza AKS teşhisi alan 20 hasta ve 20 sağlıklı birey dahil edildi. Tüm olguların plazma homosistein düzeyleri ölçülerek, hasta ve sağlıklı birey grupları arasında istatistiksel farklılık olup olmadığı araştırıldı. Ayrıca kontrol ve hasta grupları cinsiyet ve sigara içimi gözönüne alınarak alt gruplara ayrılarak plazma homosistein düzeyleri yönünden istatistiksel olarak analiz edildiler. Bulgular: Çalışmamızda, AKS tanısı almış 20 hastanın plazma homosistein düzeyleri kontrol grubundan yüksek bulundu ancak istatiksel anlamlılıkta fark bulunamadı (p>0.05). Kontrol grubu ve hasta grubu sigara alışkanlıklarına göre alt gruplara ayrılarak homosistein düzeyleri karşılaştırıldı. Hasta grubunda sigara içen olguların plazma homosistein düzeyleri içmeyenlere göre anlamlı olarak yüksek bulundu (p<0.05). Sonuç: Olgu - kontrol çalışmaları ve bazı meta-analizler yüksek plazma homosistein düzeylerinin koroner arter hastalığı için risk faktörü olduğunu bildirmektedir. Bizim çalışmamızda da hasta ve kontrol grubu homosistein düzeyleri arasında anlamlı fark bulunmuştur. Ancak devam eden, uzun süreli primer ve sekonder korunma çalışmalarının sonuçları ile açığa kavuşabilecektir

🔖

Cite This Article

DEMİRCİ, C., ÖZBAKKALOĞLU, M., YILDIRIM, A., ÇAKMAK, T., YAVUZGİL, C. (2003). Plasma homocystein levels in acute coronary syndrome patients. SSK Tepecik Eğitim Hastanesi Dergisi, Cilt: 13 - Sayı: 2, 91–96. https://ajindex.com/articles/312869

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Solberg LA, Enger SC, Hjermann I. Risk factors for coronary and cerebral atherosclerosis in Oslo Study. In: Gotto AM, Smith LC, Allen B, editors. Atherosclerosis. 5th ed. New York: Springer Verlag; 1980. p. 57-62
  2. Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey LP. Disordered methionine/homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy and enzymology. Atherioscler Thromb 1993; 13:1253-60
  3. Refsum H, Fiskerstrand T, Guttormsen AB, Ueland PM. Assessment of homocysteine status. J Inherit MetabDis 1997;20:286-94
  4. Grag UC, Zheng ZJ, Folsom AR. Short-term and longterm variability plasma homocysteine measurement. ClinChem 1997;43:141-5
  5. Morris K. Higher estrogen level linked to decreased homocysteine concentration in women. Am J Epidemiol 2000; 152:140-8
  6. Me Cully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:lll-28
  7. Kang SS, Wong PW, Malinow MR. Hyperhomocystenemia as risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12:279-98
  8. Bushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assesment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57
  9. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollest SE. Plasma homocysteine levels and mortality in patients coronary artery disease. N Engl J Med 1997;337:230-6
  10. Nygard O, Vollset SE, Refsum H. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA 1995;274: 1526-33
  11. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332:328-9
  12. Graham IM, Daly LE. Plasma homocysteine as a risk factor for vascular disease: the Europen Concerted Action Project. JAMA 1997;277:1775-81
  13. Carol J. Boushey, Shirley A, Beresford A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274(13):1049-57
  14. Clarke R, Daly R, Robinson K. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55
  15. Harker LA, Ross R, Slichter SJ, Scott CR. Homo- cysteine induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Inves 1976;58:731-41
  16. Tsia JC, Perella MA, Yoshizumi M. Promotion of vascular smooth cell growth by homocysteine: a link to atherosclerosis. Pr